Latest Conference Articles

July 23rd 2021, 1:00pm

ASCO Direct Highlights

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

July 19th 2021, 8:40pm

International Congress on the Future of Breast Cancer East

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

July 19th 2021, 8:22pm

International Congress on the Future of Breast Cancer East

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

July 19th 2021, 7:28pm

International Congress on the Future of Breast Cancer East

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

July 17th 2021, 10:00am

International Congress on the Future of Breast Cancer East

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

July 16th 2021, 8:15pm

International Congress on the Future of Breast Cancer East

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

July 12th 2021, 9:01pm

European Association of Urology Congress

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

July 12th 2021, 8:57pm

European Association of Urology Congress

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

July 12th 2021, 6:50pm

European Association of Urology Congress

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

July 12th 2021, 5:52pm

European Association of Urology Congress

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

July 10th 2021, 4:55pm

European Association of Urology Congress

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

July 10th 2021, 4:47pm

European Association of Urology Congress

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

July 10th 2021, 1:08pm

European Association of Urology Congress

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

July 10th 2021, 1:01pm

European Association of Urology Congress

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

July 9th 2021, 4:58pm

European Association of Urology Congress

The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.

June 29th 2021, 10:06pm

PER® International Congress on Oncology & Pathology: Towards Harmonization of Pathology and Oncology Standards

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

June 29th 2021, 9:25pm

PER® International Congress on Oncology & Pathology: Towards Harmonization of Pathology and Oncology Standards

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

June 29th 2021, 8:50pm

PER® International Congress on Oncology & Pathology: Towards Harmonization of Pathology and Oncology Standards

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

June 29th 2021, 2:01pm

ASCO Direct Highlights

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

June 14th 2021, 4:00pm

European Hematology Association Congress

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.